Puma Biotechnology (NASDAQ: PBYI) — Perfil da empresa, notícias e dados financeiros
Puma Biotechnology develops cancer therapies, including neratinib for HER2-positive breast cancer, aiming to enhance patient outcomes.
Puma Biotechnology
Puma Biotechnology (NASDAQ:PBYI) is a biopharmaceutical company focused on developing and commercializing innovative products to enhance cancer care. It specializes in acquiring and developing novel therapeutics for the treatment of various forms of cancer. One of its key projects includes the development of neratinib, an oral medication designed for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Puma Biotechnology aims to advance its research and development efforts to introduce new cancer therapies that can potentially improve patient outcomes and quality of life. Its objectives include expanding the indications for its existing products, advancing its pipeline through clinical trials, and seeking strategic partnerships to enhance its operational capabilities and market reach.
Resumo
Operações
Produtos e/ou serviços de Puma Biotechnology
- Neratinib (Nerlynx) - An oral tyrosine kinase inhibitor used for the treatment of HER2-positive breast cancer.
- Breast cancer clinical trials - Ongoing trials to explore the efficacy of neratinib in various settings.
- Extended adjuvant treatment research - Studies focused on improving outcomes for early-stage HER2-positive breast cancer patients.
- HER2 mutation-targeted therapies - Developing treatments specifically for patients with HER2 mutations.
- Global expansion efforts - Expanding the availability of their flagship product, Nerlynx, into new markets.
- Patient support programs - Offering educational and financial support to patients undergoing treatment with their products.
equipe executiva do Puma Biotechnology
- Alan H. AuerbachFounder, Chairman, President, CEO & Secretary
- Maximo F. NouguesCFO & Principal Accounting Officer
- Douglas HuntChief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer
- Gordon G. EsplinChief Accounting Officer
- Mariann OhanesianSenior Director of Investor Relations
- Heather BlaberSenior Vice President of Marketing
- Roger L. StormsSenior Vice President of Sales
- Pamela WilsonSenior Vice President of Clinical Operations
- Petra RietschelSenior Vice President of Clinical Development
- Kenneth WieheSenior Vice President of Supply Chain & Manufacturing
Principais indicadores financeiros
Resultados divulgados pela Puma Biotechnology, em USD.
- Cap. de mercado
- 563,7 mi
- Receita (TTM)
- 231,2 mi
- P/L
- 21.4
- LPA (diluído, TTM)
- 0.5
- Dividend yield
- —
- Margem de lucro
- 11.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 228,4 mi | 37,3 mi | 31,1 mi | |
| 230,5 mi | 31 mi | 30,3 mi | |
| 235,6 mi | 32,6 mi | 21,6 mi | |
| 228 mi | 23,7 mi | 2 mil |